Contact us:
973-983-7429
support@4hcm.org
66 Ford Road - Suite 213B
Denville, NJ 07834
ross • November 22, 2021
ICER Publishes Final Evidence Report and Policy Recommendations on Mavacamten for Hypertrophic Cardiomyopathy

ICER has released its evidence report and recommendations.

Here is a list of highlights:

  • All stakeholders have a responsibility to facilitate meaningful patient access to multidisciplinary centers of excellence for HCM in ways that do not exacerbate disparities.
  • The manufacturer of mavacamten should commit to sponsoring research that will address the lack of evidence on the comparative effectiveness of mavacamten versus disopyramide and septal reduction procedures.
  • The manufacturer should align the price of mavacamten with the explicit and transparent estimates of its treatment benefits for patients and families. Pricing should also be moderated to reflect the uncertainty about longer-term safety until such time as further outcomes data are generated.
  • Post-approval clinical registries should be established to detect rare side effects as well as assess the efficacy of mavacamten in more diverse populations.
  • Payers should use the FDA label as the guide to coverage policy and engage clinical experts and diverse patient representatives in considering how to address coverage issues for which there is limited or no evidence at the current time.

To read the entire report click here

HCMA Blog

April’s Topic is Genetic Testing

March 24, 2025
Who should have genetic testing, and when?
A photo-realistic image of heart, lit from behind, on a black background.

Arrhythmia is the HCMA topic for March

March 11, 2025
Health educator Sabrina Cuddy discusses common arrhythmias in HCM, like atrial flutter/fibrillation, ventricular tachycardia/fibrillation, left or right bundle branch block, PVC, PAC, and others. Some arrhythmias are harmless, while others are serious and need treatment.
Chart representing mavacamten trial results with total patients, and results in blue bar format.

Camzyos is Safe

By Gordon Fox • March 10, 2025
Camzyos provided significant reduction of obstruction. Initially all patients were obstructed (that is, they had gradients of at least 30mmHg after valsalva maneuvers). After 3 months on Camzyos, about 57% were no longer obstructed. After 6 months, about 70% had no obstruction.
More Posts
Share by: